Development of Oral Small Molecule PCSK9 Antagonist

Development of Oral Small Molecule PCSK9 Antagonist

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R44HL137449-01
Agency Tracking Number: R44HL137449
Amount: $1,348,901.00
Phase: Phase II
Program: SBIR
Awards Year: 2017
Solicitation Year: 2014
Solicitation Topic Code: NHLBI
Solicitation Number: PAR14-088
Small Business Information
1 GREAT VALLEY PKWY STE 8, Malvern, PA, 19355-1423
DUNS: 192526221
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 NABIL ELSHOURBAGY
 (610) 400-1243
 nabil.elshourbagy@shifabiomedical.com
Business Contact
 SHERIN ABDELMEGUID
Phone: (610) 400-1243
Email: sherin@shifabiomedical.com
Research Institution
N/A
Abstract
Project Summary AbstractThe epidemic of cardiovascular diseaseCVDis a global phenomenon that remains the number one cause of death throughout the worldkilling nearlymillion people per yeara number that is expected to grow tomillion byA high cholesterol level is well known risk factors for heart diseaseAlthough blood cholesterol can be lowered using a number of marketed drugsof which statins are the leading drugsonlyof patients taking these drugs are achieving the low density lipoprotein cholesterol goals set by the National Cholesterol Education ProgramNCEPFurthermorepatients with homozygous familial hypercholesterolemia who have markedly elevated cholesterol levels respond poorly to current drug therapyand are at very high risk of premature cardiovascular diseaseThese and other patients will dramatically benefit from an aggressive treatment of hypercholesterolemiaThe long term goal of this work is to develop novel orally bioavailable drugs for cholesterol loweringOur therapeutic target is the protease proprotein convertase subtilisin like kexin typePCSKPCSKcontrols the degradation of the LDL receptorLDLRin the liver and thereby contributes to cholesterol homeostasisPCSKis synthesized as a precursor protein that undergoes processingSecreted PCSKbinds to the LDL receptorLDLRand chaperones it to the degradation pathwayTo achieve our goalwe identified nanomolar orally active small molecule PCSKLDLR antagonists and demonstrated its efficacy in animal modelAs part of this Phase II proposalwe will undertake all the work required to characterize these compounds in multiple animal models for the proof of concept and conduct safety assessment in order to advance the lead compound toward IND enabling studies and clinical trials

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government